Press Releases


Latest News


Adamas Presents Additional Open-Label, Long-Term Safety and Efficacy Data on ADS-5102 at the First Pan American Parkinson's Disease and Movement Disorders Congress
Feb 28, 2017 | General Releases

Adamas to Present New ADS-5102 Data from Phase 2 Trial in Walking Impairment Associated with Multiple Sclerosis at ACTRIMS Forum 2017
Feb 17, 2017 | General Releases

Adamas Outlines Key 2017 Priorities and Highlights 2016 Achievements
Jan 8, 2017 | General Releases

Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
Jan 6, 2017 | General Releases

Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy
Jan 3, 2017 | General Releases

Adamas Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference
Nov 15, 2016 | General Releases

Adamas Reports Third Quarter 2016 Financial Results
Nov 3, 2016 | Financial Releases

Adamas Pharmaceuticals to Present at the Stifel 2016 Healthcare Conference
Nov 1, 2016 | General Releases

Adamas Submits New Drug Application to U.S. FDA for ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
Oct 27, 2016 | General Releases

Adamas Pharmaceuticals to Present at the 25th Annual Credit Suisse Healthcare Conference
Oct 24, 2016 | General Releases

Pages:  1 2 3 4 5 6 7 8 9 10 11 12